Under the Medicines Australia agreement, PBAC considered an immediate change to the discount rate with implementation planned through updated guidelines from July 2022. That change never arrived. The committee opposed any reduction. Surely that prejudices any role for the committee in the new review. Yes, a new review.
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News

